Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Warner Chilcott, Lupin settle Loestrin 24 Fe, Femcon Fe patent litigations
Under the terms of the settlement agreement, Lupin has agreed that, except in the event of an at-risk launch by a third-party of a generic Loestrin 24 Fe
Under the terms of the settlement agreement, Lupin has agreed that, except in the event of an at-risk launch by a third-party of a generic Loestrin 24 Fe
Twilight will offer technical know-how against 26% of fully paid equity shares of Interpro Healthcare, the company said in a filing to the Bombay Stock Exchange. Interpro will
Lewis will be responsible for the finance, accounting, IT, human resources and facilities functions and also becomes part of the company’s executive management team which directs all aspects
A total of 524 non-professional adult AD caregivers, including those of mild, moderate and severe AD patients, were surveyed in September 2010. Majority (67%) of AD caregivers surveyed
The companies collectively have over 20 facilities, 140 printing presses, 1,900 associates globally. The partnership agreement is expected to provide a strong basis for an intensive operational cooperation
Under the agreement, BioLineRx acquires all rights to develop, sub-license and commercialise the compound. BioLineRx will cover all future costs of the program. Santhera will receive 22% to
As part of the realignment, around 10 and 15 employees will move from Birmingham to Durham. This will result in the elimination of eight jobs, which will be
Under the brand name Conbriza, the drug will also be marketed in Spain through a co-promotion with Almirall, an international pharmaceutical company based in Spain. Viviant, a selective
Nefecon is an oral small molecule product which downregulates the inflammatory process in the kidneys. Nefecon is being co-developed by Pharmalink and Archimedes Pharma under a partnership agreed
The grant is in response to the solicitation ‘Recovery Act Limited Competition: NIH Director’s Opportunity for Research in Five Thematic Areas (RC4),’ funded by the American Recovery and